Results 131 to 140 of about 1,616,748 (350)

The core competencies in hospital medicine: Procedures 2025 update

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract This article presents an updated framework from the Society of Hospital Medicine for individual learning objectives related to key procedures in hospital medicine. Building upon the 2017 framework, these objectives have been revised to reflect evolving clinical evidence, advancements, and shifts in hospital medicine practice patterns.
Satyen Nichani   +8 more
wiley   +1 more source

Mortality after broad‐ versus narrow‐spectrum antibiotic treatment for patients with nursing and healthcare‐associated pneumonia: A nationwide retrospective cohort study

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background Nursing and healthcare‐associated pneumonia (NHCAP) is defined as pneumonia occurring in individuals with frequent healthcare contact, such as residents of care facilities or patients with impaired activities of daily living. The effectiveness of broad‐spectrum antibiotics in treating NHCAP remains unclear.
Jumpei Taniguchi   +4 more
wiley   +1 more source

Low‐value care and variation in practice in the care of children hospitalized with bronchiolitis in Canada (CareBEST): Protocol for a multi‐center prospective cohort study

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Introduction Low‐value care refers to health services for which the potential harms or costs outweigh the benefits of use. Bronchiolitis is the most common and among the most costly causes of pediatric hospitalizations. Evidence consistently shows that many common tests and treatments used to manage bronchiolitis do not improve outcomes ...
Branden Bonham   +39 more
wiley   +1 more source

Derivation and validation of the Pediatric Community‐Acquired Pneumonia Severity (PedCAPS) score: A prospective cohort study

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Introduction Community‐acquired pneumonia (CAP) is a frequent and costly cause of pediatric emergency department (ED) visits and hospitalizations. Previous prognostic tools for CAP are limited by small samples, single‐center or retrospective designs, lack of generalizability to ED settings, lack of biomarkers, or limited objective data.
Todd A. Florin   +21 more
wiley   +1 more source

Surrogate measure of gut blood flow via superior mesenteric circulation on ultrasound in adults who underwent esophagectomy: A descriptive cohort study

open access: yesJournal of Parenteral and Enteral Nutrition, EarlyView.
Abstract Background Early enteral nutrition is recommended for critically ill patients. However, feeding an ischemic gastrointestinal tract with enteral nutrition may lead to gut necrosis. Although gut tolerance of enteral nutrition is assessed by various symptoms, none of them provide conclusive evidence of gut ischemia. We investigated the blood flow
Tomonori Narita   +8 more
wiley   +1 more source

Inhibition of High-Mobility Group Box 1 Protein (HMGB1) Enhances Bacterial Clearance and Protects against Pseudomonas Aeruginosa Pneumonia in Cystic Fibrosis [PDF]

open access: gold, 2012
Maria Entezari   +14 more
openalex   +1 more source

Salivary microbiota and clinical periodontal measures predicting cardiometabolic disease mortality: A nationwide survey

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Although periodontitis and oral microbiota are linked to cardiometabolic diseases (CMD), it is unclear if they similarly predict CMD mortality. We compared the predictive ability of salivary microbiota and periodontal disease measures for CMD mortality in the National Health and Nutrition Examination Survey (NHANES).
Hamdi S. Adam   +6 more
wiley   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy